🇺🇸 FDA
Patent

US 10577361

Dopamine D3 receptor antagonists having a morpholine moiety

granted A61PA61P25/18A61P25/30

Quick answer

US patent 10577361 (Dopamine D3 receptor antagonists having a morpholine moiety) held by Indivior UK Limited expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Indivior UK Limited
Grant date
Tue Mar 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P25/18, A61P25/30, A61P25/36